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The synthesis and biological properties are described of [As~‘~~‘]-/l-ANP-(7-28) (Asu, L-a-aminosuberic acid), a dicarba 
analog of p-atria1 natriuretic peptide (8-ANP, an antiparallel dimer of human a-ANP with the chains linked by 7-23’ 
and 7-23 disulfide bonds). This Asu-analog (referred to as analog III) displaced 12SI-a-ANP specifically bound to cultured 
rat vascular smooth muscle cells (VSMC) with an apparent Ki of 2.1 x 10-s M, but did not stimulate formation of intracel- 
lular cGMP at 10-8-10-5 M. Analog III inhibited the a-ANP-stimulated cGMP production in VSMC competitively with 
a pA, value of 7.45 and behaved as an antagonist of a-ANP in rat aorta smooth muscle relaxation. In addition, /I-ANP 
was also shown to inhibit the a-ANP-induced cGMP production in a dose-dependent manner. The mechanism of action 
of /I-ANP is also discussed. 
Atria1 natriuretic peptide analog; Atria1 natriuretic peptide receptor antagonist; Receptor binding; cyclic GMP production; 
Vasorelaxation; (Cultured vascular smoothmuscle cell) 
1. INTRODUCTION 
Human cardiocytes produce a potent vasorelax- 
ant and natriuretic factor called atria1 natriuretic 
peptide (ANP) in three distinct molecular forms, LY- 
, ,8- and y-ANP [ 11. a-ANP is a 28-amino-acid pep- 
tide with an intramolecular disulfide bond and is 
believed to be derived from y-ANP, which is pre- 
sent predominantly in the heart and comprises 126 
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amino acid residues including an a-ANP sequence 
at the C-terminal. &ANP is an antiparallel dimer 
of human cu-ANP, in which the two monomer 
chains are linked by Cys’-Cy~~~ and Cys”-CYSTS 
disulfide bonds [2]. &ANP has not been found in 
species other than man and its mechanism of for- 
mation as well as its physiological role remain 
unknown. 
,&ANP is reported to exhibit slower onset and 
longer duration than a-ANP in diuresis and 
natriuresis [2-41. &ANP is also known to be con- 
verted into cu-ANP when incubated with human 
plasma [5] or rat cultured vascular smooth-muscle 
cells (VSMC) [6]. In view of these facts, Itoh et al. 
[5] suggested that the slow onset and long-acting 
property of P-ANP was a consequence of its slow 
conversion into a-ANP. Recently, they have shown 
that P-ANP exogenously administered to healthy 
volunteers elicits stronger responses and longer 
duration than does a-ANP when compared on a 
molar basis. This effect has been ascribed, if not 
entirely, to the dimer-to-monomer conversion 
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which has also been shown to occur in circulation 
in vivo [7]. In spite of these observations, the ques- 
tion as to whether &ANP itself is biologically ac- 
tive is still ambiguous. 
To shed more light on the nature of @-ANP, we 
attempted here to synthesize and to examine the 
biological properties of a fi-ANP analog which 
could not be converted into the corresponding 
monomer under the usual physiological conditions. 
Since deletion of a pair of 6-residue N-terminal 
segments (l-6 and l ’ -6’) from ,&ANP had no 
significant effect on the biological properties of the 
hormone including its long-acting nature [8], we 
tried to synthesi,ze a dicarba analog of fl-ANP- 
(7-28), [Asu~*~~ ]-fl-ANP-(7-28) (referred to as 
analog III), in which an L-3-aminosuberic acid 
(Asu) residue was substituted for the cystine 
residue corresponding to Cys-7 and Cys-23 ’ in & 
ANP (fig.2). The present investigation has now 
revealed that this synthetic peptide and &ANP as 
well behave as antagonists of wANP in stimulating 
cGMP production in cultured rat VSMC. 
2. MATERIALS AND METHODS 
2.1. Materials 
Human cu-ANP and &ANP [3] were synthesized by solution 
methods in these laboratories. ‘251-labeled human (u-ANP (1800 
Ci/mmol) was purchased from Amersham and aminopeptidase 
M from Pierce. 
2.2. Peptiqe synthesis 
[Asu’,~~ ]-fl-ANP-(7-28) (analog III) was synthesized by the 
conventional solution methods as illustrated in fig. 1. An Asu- 
containing octapeptide derivative (1) corresponding to positions 
21’-28’ of &ANP was coupled successively with properly pro- 
tected fragments 8-28, 17’-20’ and 7’-16’ by the EDC-HOBt 
method to give a protected derivative of analog III (2). Com- 
pound 2 was, after removal of the Boc group wit) TFA, treate,d 
with HF-anisole-dimethylsulfide togive [Asu’,~~ , Cys(Acm)’ , 
Cys(Acm)23]-fl-ANP-(7-28) in a yield of 41%. The removal of 
Acm groups by treatment with Hg(OAc)z at pH 4 was followed 
by air-oxidation under conditions of high dilution and pH 7 to 
afford analog III in a yield of 32% after purification by pre- 
parative HPLC. [C~]D~~ -46.9’ (c 0.1, 1 M acetic acid). The 
amino acid ratio in acid hydrolysate (6 M HCl, 5% thioglycolic 
acid, llO”C, 24 h) was Asp 3.88 (4), Ser 3.37 (4), Glu 2.01, (2), 
Gly 10.06 (lo), Ala 2.08 (2), Met 1.95 (2), Asu 1.08 (l), Ile 1.97 
(2). Leu 2.01 (2), Tyr 2.02 (2), Phe 4.00 (4), Arg 6.00 (6), 
Boc-$.vGly-Asu(OH)-Asn-Ser-Phe-Arg-ig:-OH (1) , 23' , 
1 H-Phe--- Cys(Acm)---Tyr(Dcb)-O&l (8-28). EDC/HOBt 
. 
8 23 28 
rPhe---Cys(Acm)---Tyr(Dcb)-OElzl 
Boc-Leu---A&J---Tyr(Dcb)-OBzl 
21' 23' 26' 
1 TFA 
4 Boc-Ala---Gly-OH (17'-20'). EDC/HDBt 
-c TFA 
1 
Boc-Cys(Acm)---Gly-OH (7'-16'), EDC/HDBt 
rPhe---Cys(Acm)---Tyr(Dcb)-O&l 
Boc-Cys(Acm)---;;u---$(Dcb)-0821 (2) 
7' , 
1 TFA 
4 HF-anisole-dimethylsulfide 
4 Hg(OAc)2 
1 air-oxidation 
HO-Tyr-Arg-Phe-Ser-Asn-CysG1y-LeuG1y-SerG1n-Ala-G1y-I1e-Arg-Asp-Met-Arg-G1y-Gly-Phe 
I 1 
H-Cys-PheGly-Gly-ArgMet-Asp-Arg-Ile-Gly-Ala-G1n-SerGly-Leu-Gly-Asu-Asn-Ser-Phe-Arg-Tyr-OH 
analog III 
Fig. 1. Scheme for synthesis of analog III. 
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recovery 71%. Cystine was determined on an aminopeptidase M
digest: 0.91 (1). 
2.3. Culture of rat VSMC 
Vascular smooth muscle cells (VSMC) obtained from the 
thoracic aorta of 20-week-old male Wistar rats were cultured in 
virtually the same manner as described by Hirata et al. [9]. Sub- 
cultured VSMC between 6th and 10th passages were used in the 
present experiments. 
2.4. Binding experiments 
VSMC were seeded into 24-well plates (Falcon) and cultured 
to confluency. The cells were washed twice with Hank’s medium 
containing 0.1% bovine serum albumin and 2 mM Hepes (assay 
medium, 0.3 ml) and then incubated with ‘*‘I-(r-ANP in assay 
medium (0.5 ml) in the presence of different concentrations of 
peptide at 23°C for 60 min. After removal of the incubation 
medium by aspiration, the cells were quickly washed twice with 
ice-cold assay medium (0.3 ml) and solubilized with 10% SDS 
(0.5 ml) and 0.5 M NaOH (0.5 ml), successively. The cell-bound 
radioactivity was measured in a gamma counter (Aloka 
ARC-360). 
2.5. Measurements of intracellular cGMP 
The confluent VSMC in 24-well plates were washed with assay 
medium and incubated in assay medium (0.5 ml) at 37°C for 30 
min in the presence or absence of peptide. The incubation 
medium was aspirated off and ice-cold 6% trichloroacetic acid 
was added. The cells were mechanically scraped off and the mix- 
ture was centrifuged. The supernatant fluid was washed three 
times with aqueous ether and then lyophilized. The cGMP con- 
tent of the residue was measured by a radioimmunoassay kit 
(Yamasa cyclic GMP assay kit). The data obtained were analyz- 
ed by Tukey’s test [lo]. 
2.6. Assay for smooth muscle relaxant activity 
Thoracic aortae isolated from male Wistar rats (- 300 g) 
were cut into - 2 x 20 mm spiral strips and suspended in a 
modified Locke-Ringer solution, containing 120 mM NaCI, 5.4 
mM KCl, 2.2 mM CaC12, 1 .O mM MgC12,25 mM NaHCOj and 
5.5 mM glucose, at 37’C. The tissues were equilibrated for 
60-90 min under a resting tension of 1.5 g and gassed with a 
mixture of 95% 0~ and 5% CO*. The arterial strips were con- 
tracted with l-2pM PGFh in the presence or absence of analog 
III to an extent between 25 and 40% of the contraction induced 
by 30 mM KCl, and (Y-ANP was then added in a cumulative 
manner. 
3. RESULTS 
3.1. Characterization of VSMC 
The rat VSMC culture prepared according to 
Hirata et al. [9] showed a so-called hill-and-valley 
structure characteristic of smooth muscle cells. The 
Scatchard analysis was applied to the saturable 
binding of 1251-~-ANP to VSMC and gave an ap- 
parent dissociation constant (Kd) of 0.87 x 10e9 
M and the number of maximum binding sites 
30 
(Bmax) of 230000 sites/cell. These values are well 
comparable to those reported in the literature (Kd 
= 1.36 x 10m9 M, B,, = 220000 sites/cell) [9]. 
The competition of ‘251-a-ANP with unlabeled (Y- 
ANP for binding to VSMC was also analyzed by 
the Scatchard plots to give Kd = 1.2 x 10m9 M 
and B,,, = 289 000 sites/cell (literature: 
Kd = 2.4 x 10m9 M, Bmax = 278000 sites/cell 
191). 
3.2. Competitive binding to VSMC 
The ability of human a-ANP, &ANP and 
analog III to displace 1251-~-ANP specifically 
bound to VSMC was measured. The results are 
shown in fig.2. In the present experiment he Ki 
values are equivalent to the corresponding I&, 
values (concentrations of peptide displacing 50% 
of ‘251-a-ANP), since [L] is much lower than Kd in 
the equation Ki = I&/(l + [L]/Kd), where [L] 
and Kd denote the concentration and dissociation 
constant of 1251-a-ANP (111, respectively. 
Therefore, the Ki values of c~-ANP, ,&ANP and 
analog III are estimated as 2.2 x 10e9, 5.6 x 10e9 
and 2.1 x lo-* M, respectively. The relative 
loo1 
.!. 
: 
O- 
10 9 8 7 6 
-Log Cpeptidel (Ml 
Fig.2. Competition to rat VSMC of ‘*‘I-n-ANP with cu-ANP 
and related peptides. 4.2 x 10-l’ M ?-a-ANP was incubated 
with rat VSMC (approx. 1.3 x lo-’ cells) in the presence of 
various concentrations of unlabeled (Y-ANP (o), ,&ANP (A) or 
analog III (m). The experiment was performed in duplicate. 
Specific binding was determined as the difference between total 
binding and binding in the presence of 0.64 x IO-’ M unlabeled 
a-ANP. 
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potencies of &ANP and analog III calculated as 
reciprocals of their I&-, values are 0.39 and 0.1 (CJ- 
ANP = l), respectively. 
3 4. Effect on cu-ANP-induced cGMP production 
Fig.3 shows dose-response relationships for 
human (Y-ANP, &ANP and ,analog III in the pro- 
duction of intracellular cGMP in cultured VSMC. 
The production was stimulated in a dose-depen- 
dent manner by 10m9 - 10m6 M a-ANP. Less 
remarkable but significant stimulation was caused 
byfl-ANP. However, analog III did not show any 
stimulation even at lo-’ M. Then, the effect of 
analog III on the a-ANP-induced cGMP produc- 
tion was examined. In the presence of 10e7 M a- 
ANP, the intracellular cGMP level in VSMC was 
increased more than five times that of the control. 
This stimulatory effect of a-ANP was, however, 
diminished by 20, 50, and 80% in the presence of 
10e7, 10m6, and low5 M analog III, respectively 
(fig.4). &ANP also exerted a similar inhibitory ef- 
fect in the same system (not shown). The apparent 
ICSO values of analog III and ,&ANP are 
5.86 x 10m7 and 2.13 x lo-’ M, respectively. 
0 
QkF 6 
9 a 7 6 5 
-Log Cpeptidel (Ml 
Fig.3. Effect of (u-ANP (o), &ANP (A) and analog III (m) on 
intracellular cGMP production in rat VSMC. Results expressed 
as means + SE (N = 4). Asterisks indicate significant difference 
vs control (* pCO.05, ** p<O.Ol). 
The effect of analog III on the dose-response 
relationship of a-ANP was then investigated in 
terms of cGMP production in cultured VSMC. The 
results are shown in fig.5. The dose-response curve 
of wANP moves toward higher doses as the con- 
centration of analog III is increased, while the max- 
imum response of (Y-ANP appears to remain un- 
changed. From these results the EDSO values of cy- 
ANP were estimated as 3.9 x lo-* M in the 
absence of analog III and 1.4 x 10e7, 4.5 x 10m7, 
8.9 x 10e7 and 3.5 x 10e6 M in the presence of 
1 x 10-7, 3 x 10m7, 1 x 10T6 and 3 x 10T6 M 
analog III, respectively. The Schild plots [12] of 
these data are shown in fig.6, in which the 
[ED50/(ED& - l] values are plotted vs concentra- 
tion of analog III on a logarithmic scale, where 
(EDso) denotes an EDso in the absence of analog 
III. There exists a good correlation giving an equa- 
tion of y = 0.99x + 7.3 and a correlation coeffi- 
cient r = 0.99. From the intercept on the abscissa 
a pA2 value of 7.45 was obtained for analog III as 
competitive antagonist. 
control a b c d 
3.5. Effect of analog III on wANP-induced 
vasorelaxation 
Fig.4. Inhibition of intracellular cGMP production by analog 
III in rat VSMC. Cells were incubated with lo-’ M c~-ANP in 
the absence (a) or presence of lo-’ (b), 10m6 (c) or 10m5 M (d) 
analog III. Control contains no peptide. Results expressed as 
Fig.7 shows the dose-response relationship of (Y- means f SE (N= 4; * ~~0.05, ** ~~0.01). 
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Fig.5. Effect of analog III on the dose-dependent cGMP pro- 
duction of cu-ANP in rat VSMC. Cells were incubated with 
various concentrations of a-ANP in the absence (0) or presence 
of 10-‘(O), 3 x 10-‘(w), lO-6(O), 3 x 10e6 M(A)analogIII. 
The experiment was peformed in duplicate. The maximim pro- 
duction of cGMP was estimated to be 16.3 pmol per 3 x 10’ 
cells as an average value of those for four different concentra- 
tions of cu-ANP from 7 x lo-’ to 9 x lo-’ M in the absence of 
analog I II. 
J 
l 
/ 
-Log [analog 1111 (M) 
Fig.6. Schild plots for analog III in inhibition of cr-ANP- 
induced cGMP production in rat VSMC. EDso and (ED_+, 
concentrations of cu-ANP inducing 50% of the maximum 
response in the presence and absence of analog III, respectively. 
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Fig.7. Effect of analog III on vasorelaxation induced by LY- 
ANP. a-ANP was cumulatively added to the rat aortic strips 
partially contracted with PGFza in the absence (0) or presence 
of lo-’ (A) or 10e6 M (m) analog III. Relaxations induced by 
0.1 mM papaverine hydrochloride were taken as 100%. Results 
expressed as means + SE (N = 5). 
ANP in the relaxation of arterial strips previously 
contracted with PGFh in the presence or absence 
of analog III. The EDso value of cu-ANP was 4.6 
(+ 1.2) x 10-i’ M when strips were contracted in 
the absence of analog III (control), and increased 
to 9.4 (+ 4.0) x 10-i’ and 19.2 (+ 3.5) x lo-” 
M (increase, p < 0.01, Tukey’s test) in the presence 
of 1 x lo-’ and 1 x 10e6 M analog III, respec- 
tively. When tissues had previously been relaxed 
with 1 x 10e9 M a-ANP, however, no contraction 
occurred upon addition of 1 x 10v6 M analog III 
(not shown). 
4. DISCUSSION 
In a previous report, we synthesized /3-ANP- 
(7-28) and found that the deletion of a pair of 
6-residue N-terminal segments from ,&ANP had no 
significant effect on biological properties of P- 
ANP, especially on its natriuresis [8]. Here, we 
have tried to synthesize a dicarba analogue 
[A~u’*‘~]-fi-ANP-(7-28), termed analogue III, in 
which one of the two S-S bonds of fl-ANP-(7-28) is 
replaced by a CHz-CHZ linkage and one of the two 
N-terminal amino groups is deleted (fig. 1). In con- 
trast to&ANP, which tends to be converted into cr- 
ANP when incubated with human plasma [5] or 
cultured rat VSMC [6], analog III does not under- 
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go such conversion under the usual physiological 
conditions because of the presence of an Asu 
residue in the molecule. 
We have found in a preliminary experiment hat 
[Asu’,‘~ ]-fi-ANP-(7-28) (analog III) is much less 
active (< l(70) than&ANP in smooth muscle relax- 
ation in vitro and behaves as a weak partial agonist 
in natriuresis in anesthetized rats (unpublished). 
On the other hand, Watanabe et al. [13] reported 
that a deamino-dicarba analog of cu-ANP, 
[A~tt’,‘~]-c~-ANP-(7-28), was less active (- 10%) 
than a-ANP in vasorelaxation in vitro and 
natriuresis in rats, in which they found, however, 
that the maximum responses to this monomeric 
analog were the same as those to (r-ANP when the 
concentration was sufficiently high. Therefore, the 
dimer seems to be affected more markedly by the 
substitution of an amino suberic acid for a cystine 
residue than the monomer. This cannot be explain- 
ed as a sole effect of the substitution, but should be 
ascribed more to the fact that the substituted imer 
can no longer be converted into the corresponding 
monomer. Thus, the dimer-to-monomer conver- 
sion seems to be of critical importance for ,&ANP 
in manifestation of its biological activities. 
It is generally accepted that cGMP mediates 
vascular smooth muscle relaxation evoked by CY- 
ANP [14]. cu-ANP has specific receptors on 
cultured rat VSMC and is known to stimulate intra- 
cellular guanylate cyclase [9]. In this respect we 
have been trying to measure cGMP production in 
VSMC for characterization of synthetic ANP 
analogs. The cultured cells used were found to be 
identical with those established by Hirata et al. [9] 
with respect to the dissociation constant and the 
maximum binding sites for a-ANP. 
In the present investigation, we have found that 
the ability of analog III to displace i2%-ANP 
specifically bound to VSMC is l/ 10 that of a-ANP 
and l/4 that of ,&ANP (fig.2). In spite of this con- 
siderable binding to cells, analog III did not 
stimulate cGMP production in VSMC even at 
10m5 M, while cu-ANP exhibited remarkable 
stimulation with an EDso value of 3 x lo-* M 
(fig.3). These results suggest that analog III is 
either a competitive antagonist of cu-ANP or a so- 
called clearance receptor (C-receptor) agonist, 
which is able to bind to the C-receptor but not to 
the bioactive receptor (B-receptor), only the B- 
receptor being coupled to guanylate cyclase 
[14,15]. We therefore examined analog III with 
special reference to its effect on the a-ANP- 
induced production of intracellular cGMP in 
VSMC. The results shown in figs 4 and 5 clearly in- 
dicate that analog III is a specific antagonist of (Y- 
ANP. The Schild analysis [12] of these data has 
revealed that the inhibitory profile of analog III is 
competitive and its pA2 value is 7.45 (fig.6). Thus, 
it has become clear that analog III binds to the 
guanylate cyclase-coupled ANP receptor but fails 
to stimulate the enzyme, probably because of the 
lack of dimer-to-monomer conversion at the recep- 
tor site. This antagonism of analog III has also 
been observed in cu-ANP-induced relaxation of rat 
aortic strips (fig.7). This observation supports the 
view that the signal transduction of a-ANP is 
mediated by cGMP in vasorelaxation. However, 
the antagonism was observed only when analog III 
was introduced at the stage of contraction with 
PGFza and prior to the addition of (u-ANP. The 
tissues once dilated with a-ANP were not con- 
tracted by the addition of analog III. The precise 
mechanism of signal transduction of a-ANP in 
smooth muscle relaxation, therefore, remains to be 
elucidated. 
Although the characteristic pattern of action of 
,&ANP in vasorelaxation and natriuresis [2,3] may 
be explained, at least in part, by the slow conver- 
sion of ,&ANP into a-ANP in human plasma or at 
target tissues [5-7,161, it has been a matter of con- 
troversy as to whether fl-ANP itself is biologically 
active. The present investigation has also shown 
that ,&ANP inhibits the a-ANP-induced produc- 
tion of intracellular cGMP in cultured VSMC with 
an apparent ICSO value of 2.13 x lo-’ M, which is 
about one-third that of analog III and this ratio is 
comparable to that one between the 1% values of 
&ANP and analog III for receptor binding. This 
finding as well as those described above strongly 
suggests that &ANP is inherently inactive, if not 
completely inactive, and can even behave as a com- 
petitive antagonist of a-ANP as long as it exists in 
the form of dimer. However, the detailed 
mechanism of vasorelaxation and natriuresis of ,& 
ANP remains to be elucidated. 
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